Diabetes treatment with hypolipidemic drugs and study ASPEN
Authors:
Š. Svačina
Published in the journal:
Kardiol Rev Int Med 2006, 8(3): 112-113
Category:
Editorial
Summary
Type 2 diabetic patients are in extreme cardiovascular risk. The studies ASCOT-LLA a CARDS have showed a significant reduction of cardiovascular risk in diabetes using 10 mg atorvastatin. Recently finished the FIELD study did not show any significant risk reduction using fibrate. Statin was more frequently used in the placebo group and this could reduce the effect of fibrate in the comparison of both groups. 10 mg atorvastatin or placebo were used in the ASPEN study in type 2 diabetic patients in primary and secondary cardiovascular disease prevention. The design of the study and the changing guidelines cause two times higher use of other hypolipidemic drugs in the placebo group. ASPEN study does not bring controversies to older statin studies.
Keywords:
type 2 diabetes – statin – fibrate – cholesterol – macrovascular complications
Zdroje
1.Svačina Š et al. Cévní komplikace diabetu. Praha: Galén 2005.
2.Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
3. Svačina Š. Diabetes a hypolipidemika. In: Svačina Š et al. Cévní komplikace diabetu. Praha: Galén 2005.
4. Šmahelová A. Necholesterolové steroly a diabetes 2. typu. In: Svačina S. Trendy v diabetologii. Praha: Galén 2005. Vol 10.
5.Sever PS, Poulter NR, Dahlof B et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005; 28: 1151-1157.
6.Colhoun HM et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
7.FIELD Study GROUP. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-910. Erratum in: Lancet 2001; 357: 1890.
8.Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006; 29: 1478-1485.
Štítky
Paediatric cardiology Internal medicine Cardiac surgery CardiologyČlánok vyšiel v časopise
Cardiology Review
2006 Číslo 3
Najčítanejšie v tomto čísle
- Non-invasive examination in arterial hypertension
- Losartan – more than blood pressure decrease
- Remote monitoring of implantable pacemakers and cardioverters-defibrillators
- Treatment of diabetes mellitus in cardiac patients